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Abstract
Objectives: It is essential to understand the molecular basis of ovarian cancer etiology and tumor development to 
provide more effective preventive and therapeutic approaches to reduce mortality. Particularly, the molecular targets 
and pathways involved in early malignant transformation are still not clear. Pro-inflammatory lipids and pathways have 
been reported to play significant roles in ovarian cancer progression and metastasis. The major objective of this study 
was to explore and determine whether platelet activating factor (PAF) and receptor associated networking pathways 
might significantly induce malignant potential in BRCA1-mutant at-risk epithelial cells.
Methods: BRCA1-mutant ovarian epithelial cell lines including (HOSE-636, HOSE-642), BRCA1-mutant ovarian cancer 
cell (UWB1.289), wild type normal ovarian epithelial cell (HOSE-E6E7) and cancerous cell line (OVCA429), and the non-
malignant BRCA1-mutant distal fallopian tube (fimbria) tissue specimens were used in this study. Mutation analysis, 
kinase microarray, western blot, immune staining, co-immune precipitation, cell cycle, apoptosis, proliferation and 
bioinformatic pathway analysis were applied.
Results: We found that PAF, as a potent pro-inflammatory mediator, induced significant anti-apoptotic effect in BRCA1-
mutant ovarian surface epithelial cells, but not in wild type HOSE cells. With kinase microarray technology and the 
specific immune approaches, we found that phosphor-STAT1 was activated by 100 nM PAF treatment only in BRCA1-
mutant associated at-risk ovarian epithelial cells and ovarian cancer cells, but not in BRCA1-wild type normal (HOSE-
E6E7) or malignant (OVCA429) ovarian epithelial cells. Co-immune precipitation revealed that elevated PAFR expression 
is associated with protein-protein interactions of PAFR-FAK and FAK-STAT1 in BRCA1-mutant ovarian epithelial cells, but 
not in the wild-type control cells.
Conclusion: Previous studies showed that potent inflammatory lipid mediators such as PAF and its receptor (PAFR) 
significantly contribute to cancer progression and metastasis. Our findings suggest that these potent inflammatory 
lipids and receptor pathways are significantly involved in the early malignant transformation through PAFR-FAK-STAT1 
networking and to block apoptosis pathway in BRCA1 dysfunctional at-risk ovarian epithelium.
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Background
The combination of mutation and aberrant expression of
tumor suppressor genes is critical in cancer susceptibility
and tumor progression. BRCA1 protein plays multiple
essential functions such as tumor suppressor, transcrip-
tional regulation and DNA repair in normal epithelial
cells and stem cells [1]. An inherited BRCA1-mutation
confers an increased risk of ovarian cancer, with lifetime
risk estimates ranging from 10-60%, compared to a risk of
less than 2% for the general population [2-4]. About 10%
of women presenting with ovarian cancer carry a BRCA-
mutation. Previous publications indicate that a BRCA1
mutation is associated with cancer progression through
pathways of cell proliferation [5], differentiation [6], and
apoptosis [7]. It is known that loss of BRCA1 function
may ultimately activate JAK-STAT pathways and stimu-
late cell proliferation in breast, prostate, lung and ovarian
cancer [8,9]. But it is still unclear what molecular mecha-
nisms and targets characterize the early molecular events
of malignant transformation.
Chronic inflammatory microenvironments have been
hypothesized as the major factors predisposing ovarian
[10,11] and other cancers [12]. Lipid mediators such as
lysophosphatidic acid (LPA) and prostaglandin with their
associated receptors and pathways such as COX have
been shown to play a critical role in cancer initiation and
progression [13,14]. Unfortunately, platelet activating fac-
tor (PAF, 1-O-alkyl-2-acetyl-sn-glycero-3-phosphoryl-
choline), as one of the most potent lipid mediators, has
not yet been well studied in the regulation of early events
of cancer transformation and progression [15], particu-
larly with the at-risk in vitro and in vivo models. PAFR
belongs to the G protein-coupled receptor (GPCR) pro-
tein family, and transduces cell signals via the G proteins
and associated protein phosphorylation cascades [16,17].
When cells are exposed to PAF, it induces cell prolifera-
tion, activates tyrosine kinase [18] and protein phospho-
rylation [19] in human epithelial cells, skin fibroblasts
[20], endothelial cells [21], lung fibroblasts cells [22], pul-
monary vascular smooth muscle cells [23] and keratino-
cytes [24]. PAF plays significant roles in many biological
pathways in inflammatory diseases and cancer progres-
sion [25,15,26]. Upon PAF/PAFR activation, the Signal
Transducers and Activators of Transcription (STAT)
pathways are activated by phosphorylation changes,
dimerization, and translocated into the nucleus to acti-
vate transcription of specific genes in regulation of cellu-
lar functions [18,27]. Our earlier study demonstrated that
platelet activating factor (PAF) and PAFR play a signifi-
cant role in ovarian cancer progression and invasion
through activation of a set of tyrosine phosphor-EGFR/
Src/FAK/Paxillin[15]. In this study, we investigate the
possibility that inflammation associated lipid mediator
PAF might mediate the early BRCA-carcinogenic events
using an in vitro at-risk model employing cancerous and
non-cancerous ovarian BRCA1-mutant epithelial cells
with over expression of PAFR.
Methods
Chemical reagents
DMSO, PAF, and ginkgolide B (>90% high-performance
liquid chromatography grade), cell culture mediums of
MCDB-105 and medium 199 were obtained from Sigma-
Aldrich (St. Louis, MO). MEGM mammary epithelial cell
growth medium was purchased from Lonza (Walkers-
ville, MD) and RPMI 1640 from Invitrogen (Carlsbad,
CA). CV-3988 (a selective inhibitor of PAFR) was pur-
chased from Biomol International L.P (Plymouth Meet-
ing, PA). Rabbit polyclonal antibody against PAFR was
purchased from Cayman chemical company (Ann Arbor,
Michigan). Phospho-kinase array kit and polyclonal anti-
body against phosphor-STAT1 was purchased from R&D
(Minneapolis, MN). Rabbit polyclonal antibody against
STAT1 and monoclonal antibody against FAK were pur-
chased from Cell Signaling Technology (Boston, MA) and
Invitrogen-Biosource International Inc. (Carlsbad, CA),
respectively.
Immortalized BRCA1-mutant human ovarian surface
epithelial cells (HOSE-636, and HOSE-642) were gener-
ated from women who underwent prophylactic
oophorectomies because of predisposing BRCA1 muta-
tion. Immortalized normal human ovarian surface epi-
thelial cells (HOSE-E6E7 and HOSE-27) were derived
from primary cultured cells of the fresh ovarian scrapings
at the time of surgery for benign ovarian conditions with-
out BRCA1 mutation. The UWB1.289 (here after referred
to as UWB1) cell line is a serous-type ovarian cancer with
a BRCA1 mutation (ATCC American Type Culture Col-
lection, Manassas, VA) and OVCA429 cell line is a serous
ovarian cancer without a BRCA1 mutation.
Cell lines and cell culture
HOSE-E6E7, HOSE-27, HOSE-636, HOSE-642, and
OVCA429 were cultured in M199/MCDB-105 with 15%
fetal bovine serum (Gemini Bioproducts, West Sacra-
mento, CA) and 1% antibiotic (200 mmol/L L-glutamine,
10,000 units penicillin, and 10 mg/mL streptomycin).
UWB1 cells were cultured in MEGM/RPMI with 3% fetal
bovine serum and 200 μg/ml Geneticin (GIBCO-Invitro-
gen, Carlsbad, CA). Cell culture conditions were main-
tained at 37°C under 5% CO2 and 95% air in a high-
humidity chamber. All non-commercial cell lines were
constructed from material collected under IRB approved
protocols for collection of "de-identified" human subjects.
BRCA1 mutation characterization analysis
BRCA1 exon sequence analysis: Genomic DNA was iso-
lated from HOSE-636 cells with the Puregene Trial kitZhang et al. Reproductive Biology and Endocrinology 2010, 8:74
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(Gentra Systems, Inc.), following the manufacturer's
instructions. DNA was precipitated using a standard pro-
tocol using saturated NaCl and isopropanol. The DNA
pellet was washed with 75% ethanol, air dried, and resus-
pended in Tris-EDTA (50 mM, pH6.8). Direct DNA
sequencing for BRCA1  was done for all coding exons
using Big Dye Terminator chemistry and an automated
3100 DNA sequencer (Applied Biosystems, Foster City,
CA). In addition, HOSE-636, HOSE-642 and UWB1 cells
with BRCA1 mutation were certified having the BRCA1
protein truncation by Western Blot according to the pub-
lished method [28].
Western blot
The cultured cells were washed twice with 1 × PBS and
lysed with ice-cold cell lysis buffer (Cell Signaling Tech-
nology, Boston, MA). Protease inhibitors including phe-
nylmethylsulfonyl fluoride (1 mM) and Protease Inhibitor
Cocktail I and II (Sigma-Aldrich, St. Louis, Mo) were
freshly added to the cell lysis buffer. After a brief vortex-
ing and centrifuging at 4°C, the cell lysates were trans-
ferred to a new tube. The concentration of protein was
determined with the Bradford Protein Assay Kit (Bio-Rad
Laboratories). Protein lysates were subjected to 8-16%
SDS-PAGE gel separation followed by transferring onto
polyvinylidene difluoride membrane (Perkin-Elmer)
using the Wet Transfer Cell (Invitrogen, Carlsbad, CA)
and blocked with 5% fat-free dry milk at room tempera-
ture for 1 hour. After washing four times, membranes
were incubated with primary antibody (Anti-BRCA1
antibody, Cell Signal Technology, Boston) in blocking
solution (1:1000 dilution) at 4°C for overnight. Secondary
antibody (1:1000) tagged with HRP was used to reveal the
protein expression signals with chemiluminescent sub-
strate kit (Pierce Chemical, Co.). Similar western blot
protocol has been used for other protein detection
including PAFR, STAT1 and FAK.
Immune staining of PAFR in human tissue
Immunohistochemical analysis was performed for
detecting PAFR protein expression in sixteen wild type
and eight BRCA1-mutant patients using the EnVision/AP
system (DakoCytomation) which used an anti-rabbit
immunoglobulin conjugated to an alkaline phosphatase
polymer (Labeled polymer-AP) with a red stain as posi-
tive after the addition of the Substrate-Chromogen solu-
tion. Slides were washed with deionized water and
counterstained with hematoxylin and 5% ammonium
hydroxide, and mounted in Accergel (Accurate Chemical
and Scientific Corp). The image was recorded by a digital
camera (Optronic Inc.). Human pancreatic tissue sec-
tions were used as a positive control.
Cell treatment and proliferation assay
Cell proliferation was assessed by using a 3-(4,5-dimeth-
ylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT)
assay (Promega, Madison, WI). Monolayer cells at 60-
80% confluence were enzymatically removed using
trpysin/EDTA and plated in 96-well flat-bottomed plates
at a concentration of 1 × 105 per well. After overnight
plating and starving for 24 h in FBS free medium, HOSE-
E6E7, HOSE-27, HOSE-636, HOSE-642, and UWB1 cells
were treated with different concentrations of PAF in 0.5%
FBS medium daily for 3 days, raging from 0.1 nM to 100
nM. For details of PAF treatment and MTT assay, see our
previous publication [15].
Cell cycle and apoptosis analysis
Immortalized human ovarian surface epithelial cells
HOSE-E6E7and HOSE-642 were rendered at confluence
by incubation in M199/MCDB105 medium with FBS free
overnight. After treatment with 100 nM PAF 24 and 72 h,
cells were harvested and fixed with 70% cold ethanol in
PBS buffer by suspending the cell pellet and incubating at
-20°C within 7 days. The cells were resuspended in PI
master mix (PI:40 ug/ml and RNase:100 ug/ml in PBS
buffer without Ca2+ and Mg2+) at a final cell density of 0.5
× 106 cells/ml. After transferring to a Falcon 2054 (Fisher#
149592A) tube and incubation at 37°C for 30 minutes,
cells were subjected to analysis using a FACS Calibur™
Flow Cytometer (Becton-Dickson, San Jose, CA). Each
experiment was repeated three times and the cell cycle
profiles, apoptosis index were analyzed by ModFit LT
software (Verity Software House, Inc., Topsham, ME)
[29].
Kinase microarray analysis
UWB1 cells were incubated in fresh RPMI/MEGM FBS-
free medium overnight at 37°C in a humidified chamber,
which were pretreated with ginkgolide B (GB,100 μM, as
specific PAFR antagonist) 3 h before PAF (100 nM) treat-
ment. Cells were harvested at certain time points after
treatment by twice washing with 1 × PBS, then lysed with
ice-cold cell lysis buffer (Cell Signal Technology), includ-
ing protease inhibitors.
Phospho-Kinase Array kit (R&D, Minneapolis, MN)
was used to detect the relative levels of phosphorylation
of 46 kinase phosphorylation sites. The human Phospho-
Kinase Array is divided into A and B parts with different
sets of protein kinase targets, to maximize sensitivity and
minimize cross-reactivity. Capture and control antibod-
ies were spotted in duplicate on nitrocellulose mem-
branes (A and B). First, the membranes were incubated
with 1 mL of blocking buffer in 8-Well Multi-dish for 1 h
on a rocking platform. About 310 μg of fresh protein
lysates were diluted in 1 ml array buffer 1 (1:5) and incu-Zhang et al. Reproductive Biology and Endocrinology 2010, 8:74
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bated (A and B membrane) overnight at 4°C. Membranes
were then removed to the same container and washed 3
times using 1 × washing buffer. A detection antibody
cocktail (for A and B membrane, respectively) diluted
with 1 × array buffer was incubated for 2 h at room tem-
perature. After an additional 3 washes, 30 min for each,
streptavidin-HRP (1:2000) was used to reveal protein
phosphorylation by chemiluminescent kit (Pierce Chemi-
cal, Co.) and quantified via an Axon Genepix scanner
(Molecular Devices, Co.) and analyzed with ArrayVision
software.
Co-immunoprecipitation
A 400 μg protein lysate of HOSE-642 cells with PAF treat-
ment were incubated with 5 μg antibodies of P AFR or
phosphor-PAK with 400 μL immunoprecipitation buffer
for 2 hours at 4°C. Protein A/G agarose beads were added
for overnight incubation. After five times wash, the pro-
tein of interest was eluted by SDS/reducing sample buffer
and boiling for 3 min and then subjected to 7.5% SDS-
PAGE gel separation. The protein was transferred to
PVDF membrane (Perkin-Elmer) using the wet transfer
cell (Invitrogen, Carlsbad, CA) and blocked with 5% fat-
free dry milk at room temperature for 1 hour. After wash-
ing four times, membranes were incubated with different
primary antibodies phosphor-FAK (1:1000 dilution) for
PAFR co-immuneprecipitation, and PAFR (1:1000 dilu-
tion) for FAK co-immuneprecipitation, respectively, at
4°C overnight. Following an additional three washes, pro-
tein expression signals were detected by HRP with chemi-
luminescent kit (Pierce Chemical, Co.) as described
before. Protein IgG was used as control to confirm the
immune specificity of protein-protein interaction and
precipitation. A similar approach was used to define the
protein-protein interaction between FAK and STAT1.
Statistical analysis
The phosphor-kinase array data were analyzed by Origin
7.0 software. All other data were analyzed by using one-
way factorial analysis of variance tests. Data collected
from the treated and untreated cells with different dose
or at different time point were analyzed by paired t-test
and ANOVA test, respectively. The significance of pro-
tein expression on western blots and the immune staining
intensity of PAFR in fallopian tube epithelial cells of
p a t i e n t s  w i t h  o r  w i t h o u t  B R CA 1 +  m u t a t i o n  w e r e  a n a -
lyzed by paired Student t-test.
Results
Characterization of BRCA1 mutation and over expression of 
PAFR in BRCA1 mutation ovarian epithelial cell lines and 
fallopian tube surface epithelial cells
DNA sequencing analysis of the germline DNA isolated
from HOSE-636 cells revealed a mutation at 1961delA
(with a stop codon at 700 of BRCA1) relative to the wild
type BRCA1 sequence in HOSE-E6E7 cells (Fig. 1A). In
addition, based on the method of [28], western blot analy-
sis of the HOSE-636, HOSE-642 and UWB1 cells showed
that the BRCA1-mutation cell lines consisted of BRCA1
truncated three peptide fragments of less than 25 kDa
(see Fig. 1B lanes 2-4). The truncated BRCA1 protein
peptides were not found in the wild-type normal ovarian
epithelial cells (Fig. 1B) and ovarian cancer cells such as
OVCA429 (data not shown).
Figure 1 Molecular characteristics of the BRCA1 mutation in 
(BRCA1+) ovarian epithelial cells. (A) DNA extracted from the HOSE-
636 and HOSE-E6E7 cells were subjected to BRCA1 gene sequence 
analysis with the standard protocol. 1961 delA mutation was detected 
in HOSE-636 cells. (B) Total protein lysis (30 μg) of Western blot showed 
pieces of mutant fragments of BRCA1 protein in HOSE-E6E7, HOSE-636 
HOSE-642, and UWB1 cells were applied on SDS-PAGE and western 
blot analysis. Intact BRCA1 protein and its fragments were revealed by 
BRCA1 antibody. The separated western blots are required because of 
the nature and working conditions are different between BRCA1 intact 
protein and the truncated peptides. (C) PAFR protein was detected by 
western blot in wild type HOSE-E6E7 and BRCA1-mutant HOSE-636, 
HOSE-642, and UWB1 cell lines with a specific polyclonal antibody 
against human PAFR. The equal protein loading was normalized by β-
actin.Zhang et al. Reproductive Biology and Endocrinology 2010, 8:74
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Western blot analysis of PAFR protein expression
revealed three protein bands corresponding to PAFR
expression with slight variations between different cell
lines. One PAFR protein band (upper) with a high molec-
ular weight was strongly detected in UWB1 cells. The
second band was specifically over-expressed in all
BRCA1-mutant ovarian epithelial cell lines (HOSE-636,
HOSE-642 and UWB1), but less expressed in wild-type
normal HOSE-E6E7 cells. The lower molecular weight
PAFR band was barely detectable, which may correspond
to the constitutive level of PAFR expression in both wild
type and BRCA1-mutant ovarian epithelial cells (Fig. 1C).
This data was consistent with our previous finding that
multiple isoforms of PAFR were expressed in human
ovarian epithelial cancer cells and in other mammalian
cells [15,30]. To further determine whether over expres-
sion of PAFR was associated with BRCA1  mutations,
immunohistochemical staining (IHC) was performed on
tubal fimbral tissue slides from women with inherited
BRCA mutations and randomly selected BRCA1 wild
type control fallopian tubes. Immunohistochemical stain-
ing for PAFR was positive in epithelial from the women
with BRCA1 mutations (Fig. 2BDFG, n = 8), but less in
the wild type controls (Fig. 2CEG, n = 16, p < 0.05).
Lipid PAF activates PAFR/BRCA1/STAT networking pathway 
in BRCA1-mutant ovarian epithelial cancer cells
Activated platelets and platelet activating factor (PAF) are
often associated with inflammatory conditions and can-
cer [31,32]. Based on the previous publications, pathway
bioinformatic software revealed that about 14 proteins
are mediated in the functional regulations and protein-
protein interactions between PAFR and BRCA1 and
majority of interactive nodes are protein kinases (Fig.
3A). To investigate whether ovarian epithelial cells with
BRCA1-mutation and PAFR-over-expression might be
particularly sensitive and responsive to the inflammatory
lipid mediators such as PAF, ovarian cancer cells (UWB1)
with BRCA1-mutant and over expression of PAFR were
treated with PAF (100 nM) for 24 hours, followed by pro-
tein phosphorylation detection and profiling using the
kinase array. Among the 46 kinase phosphorylation sites/
targets tested, we found that only one target (phosphor β-
catenin) was significantly enhanced by PAF/PAFR block-
ing agent treatment at 24 h (not shown). Many phosphor-
sites/proteins including STAT1, STAT3, STAT4, P53,
AKT, TOR, P70 and RSK were significantly (p < 0.05)
induced by PAF treatment (Fig. 3).
To further determine whether PAFR-STAT1 pathways
might be involved in malignant transformation in
BRCA1-mutant ovarian epithelial cells, wild-type ovarian
epithelial normal cells (HOSE-E6E7) and ovarian cancer
cells (OVCA429) were used as controls. BRCA1-mutant
ovarian surface epithelial non-malignant (HOSE-642,
HOSE-636) and malignant (UWB1) cells were treated
with 100 nM PAF at different time points followed by
phosphor-STAT1 detection using western blot with the
specific phosphor-antibody (R&D, Minneapolis, MN).
We found that the enhanced phosphor-STAT1 was nei-
ther observed in the wild type normal ovarian epithelial
HOSE-E6E7 cells, nor in the wild type ovarian cancer
Figure 2 Immune staining of PAFR expression in epithelial cells of 
fallopian tube fimbria of BRCA1+ patients. (A, B) Immune staining 
of epithelial cells of fallopian tube fimbria of BRCA1+ patients with and 
without PAFR antibody. (C, E) Negative PAFR staining on the BRCA1 
wild type epithelial cells of fallopian tube fimbria. (D, F) Positive im-
mune staining of PAFR in epithelial cells of fallopian tube fimbria of the 
BRCA1+ patients. (G) Summary of the intensity scale (mean value with 
standard error bar) of immune histochemistry staining of the epithelial 
cells of fallopian tube collected from the patients without (n = 16) and 
with BRCA1-muation (n = 8) (p < 0.05). The grading system (1-10) of the 
immune intensity was used for semi-quantification and same set of 
slides were read by two independent investigators.
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cells (OVCA429), but only found in BRCA1-mutant cell
lines (HOSE-642, HOSE-636, and UWB1) (Fig. 4A). In
addition, we found that PAF induced a significant
increase of both STAT1 and phosphor-STAT1 in HOSE-
636 cells, but only increased phosphor-STAT1 in HOSE-
642 and UWB1 cells (Fig. 4B). It appears that the
increased phosphor-STAT1 peaked at 20 to 60 min of
PAF treatment in BRCA1-mutant cell lines (e.g. HISE642
and UWB1) (Fig. 4C). To further investigate whether the
activation of the phosphor-STAT1 pathway in BRCA1-
mutant ovarian epithelial cells by PAF treatment is asso-
c i a t e d  w i t h  P A F R ,  w e  e x a m i n e d  t h e  e f f e c t  o f  v a r i o u s
PAFR inhibitors such as CV3988 (10 μM), PAFR antago-
nist ginkgolide B (GB, 100 μM), and specific PAFR anti-
body (1:50, data not shown) on phosphor-STAT1 in both
HOSE-642 and UWB1 cells at 20 min of treatment with
PAF (100 nM). As expected, we found that pretreatment
of CV3988, GB and PAFR antibody indeed showed signif-
icant inactivation of phosphor-STAT1 in BRCA1 muta-
tion cell lines, particularly in HOSE642 cells (Fig. 4D).
PAF induced cell proliferation, cell cycle and anti-apoptosis 
in BRCA1-mutant ovarian epithelial cells
To investigate whether nano mole concentration of PAF,
which mimics endogenous chronic inflammation,
induces a significant biological effect on cell proliferation
and apoptosis, three BRCA1-mutant ovarian surface epi-
thelial cell lines were used. Two of them were PAFR-posi-
tive normal ovarian epithelial cell lines (HOSE-642 and
HOSE-636) and one was ovarian cancer cell line (UWB1)
with PAFR over expression. In addition, two normal ovar-
ian surface epithelial cell lines (HOSE-E6E7 and HOSE-
27) BRCA1-wild type and without PAFR-over expression,
were used as controls. We found that after three days of
incubation with different concentrations of PAF, there
was a significant, as much as a 29% decrease in cell prolif-
eration in HOSE-27 (p < 0.001) and HOSE-E6E7 cells (p <
Figure 3 Bioinformatic pathway and protein-protein interaction between PAFR-BRCA1. (A). Pathway Studio software (Ariadne Inc.) and Human 
ResNet Mammalian Database were used in the study. Antibody microarray based protein kinase profiling and identification of STAT1 and STAT4 in 
BRCA1-mutant and PAFR-over expression (PAFR+) ovarian epithelial cancer cells. UWB1 cells were treated with PAF (100 nM) for 24 hours. Images of 
kinase arrays of signals after the incubation with 310 μg protein lysate of UWB1 cells treated with 100 nM PAF only (B) or with combination of 100 μM 
ginkgolide B (GB) and 100 nM PAF (C). The duplicated internal positive controls were used to calibrate the detection signal of membranes of the treat-
ed and untreated experiments. The summary of kinase expression profile of the UWB1 cells with different treatments and significance comparison by 
the paired student t-test (D).Zhang et al. Reproductive Biology and Endocrinology 2010, 8:74
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Figure 4 Activated phospho-STAT1 in BRCA1+ ovarian epithelial cells. (A) Wild type HOSE-E6E7 and OVCA429 cancer cells and BRCA1-mutant 
at-risk (HOSE-642, HOSE-636) cells and BRCA1-mutant ovarian cancer cells (UWB1) were subjected to PAF treatment for 20 minutes and phospho-
STAT1 (Y701) detection by western blot. (B) Summary of intensity of SATA1 and phosphor-STAT1 induced by PAF treatment in HOSE-642, UWB1 and 
HOSE-636 cells. Phosphor-STAT1 was significantly (p < 0.01) increased in all BRCA1-mutant cells. (C) Activation of phosphor-STAT1 at different time 
points (0, 5, 20 60 min and 360 min) of PAF treatment (100 nM) in BRCA1-mutant HOSE-642 and UWB1 cells. (D) Equal amount of protein lysate of the 
cells of untreated, treated with PAF (100 nM) alone or in combination of PAF and PAFR-inhibitor (10 μM) and GB (100 μM) were applied in western 
blot detection. DMSO and pure IgG (not shown) were used as control treatment for 20 minutes in both HOSE-642 and UWB1 cells. Equal loading of 
protein was calibrated with expression of β-actin.Zhang et al. Reproductive Biology and Endocrinology 2010, 8:74
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0.05), compared with that of controls (as 100%, Fig. 5A).
However, two non-cancerous BRCA1-mutant ovarian
epithelial cells (HOSE-642 and HOSE-636) along with
BRCA1-mutant ovarian cancer cells (UWB1) revealed a
slight and significant increases in cell proliferation (Fig.
5A) at 1, 10 and 100 nM PAF (p < 0.05). After 72 h treat-
ment with 1.0 nM PAF, cell proliferation was significantly
(p < 0.05) decreased in the wild type HOSE cells (HOSE-
27 and HOSE-E6E7). However, all three BRAC1-mutant
ovarian epithelial cells showed no significant decrease in
cell proliferation (Fig. 5B), but with slightly and signifi-
cant increases. To evaluate whether PAF induced cell pro-
liferation in BRCA1-mutant ovarian HOSE cells is
associated with PAFR expression, cells were pretreated
with PAFR inhibitor CV3988 (10 μM), PAFR antibody
(1:100) and different concentrations of PAFR antagonist
GB (1, 5, 10, 50, and 100 μM) for three hours followed by
PAF treatment (100 nM) for 72 h. We found that the cell
proliferation of all three BRCA1-mutant cells lines were
significantly decreased (p < 0.005), especially by PAFR
inhibitor and PAFR antagonist GB, compared to that of
controls with equal volume of DMSO treatment (Fig. 5C).
Different concentration of GB (1-100 μM) showed the
similar efficacy to block PAF-induced cell proliferation,
which suggests that 1 μM GB may able to reach the maxi-
mum blocking on PAF-PAFR interaction.
In addition, we examined whether cell cycle and apop-
tosis are differentially affected by PAF treatment in
BRCA1-mutant and wild type ovarian surface epithelial
cells. Interestingly, we found that the cell cycle analysis
showed no significant changes in DNA content of G2
phase. PAF (100 nM) treatment significantly induced
anti-apoptotic effects from 38.9% to 25.2%, in BRCA1-
mutant HOSE-642 cells (Fig. 5DE). As we expected, after
treatment of PAF (100 nM) for 72 hours, cell cycle analy-
sis showed that DNA content of S phase was marginally
Figure 5 PAF induced cell proliferation and anti-apoptosis in BRCA1-mutant ovarian epithelial cells. (A) The induced cell proliferation pattern 
in wild type HOSE-E6E7 and HOSE-27 cells and BRCA1-mutant HOSE-642 and HOSE-636 and ovarian malignant cells (UWB1) was affected by 72 hours 
treatment with different concentrations of PAF. Significant increase or decrease of cell proliferation induced by PAF treatment was indicated by sym-
bol star (* p < 0.05). (B) Differential cell proliferation pattern was affected by PAF (1 nM) treatment in wild type of HOSE-E6E7 and HOSE-27 cells and 
BRCA1-mutant non-malignant HOSE-642 and HOSE-636 and ovarian cancer cells (UWB1), compared to the control cells without PAF treatment (as 
100%). (C) PAFR-inhibitor, specific PAFR antibody and different concentration of antagonist ginkgolide B (1, 5, 10, 50, 100 μM) significantly (p < 0.05) 
blocked the PAF-induced proliferation in three BRCA1-mutant ovarian epithelial cell lines, compared to the control cells treated either with equal vol-
ume of DMSO or with IgG (as 100%). (D, E) Anti-apoptotic activity was significantly (p < 0.05) induced by PAF treatment in BRCA1-mutant at-risk HOSE-
642 cells. (F, G) Apoptosis was significantly induced by PAF (100 nM) in wild-type HOSE-E6E7 cells, compared to the controls with 72 h treatment of 
equal volume DMSO. Experiments were performed at least three times (p < 0.05).
Figure 5Zhang et al. Reproductive Biology and Endocrinology 2010, 8:74
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increased from 17.02(± 0.21) % to 21.8(± 4.3)% (p  =
0.058), and G2 phase was significantly decreased from
14% (± 4.0) to 6.0% (± 1.9) (p = 0.026) in HOSE-E6E7
cells. The apoptotic cell population was significantly
increased from 16.9% (± 1.5) to 70.26% (± 2.4) (p = 0.001)
in wild type ovarian surface epithelial cells (Fig. 5FG)
when compared to the control cells treated with equiva-
lent DMSO.
PAF induced activation of PAFR-FAK-STAT1 networking 
pathways in BRCA1-mutant ovarian epithelial cells
Our previous studies demonstrated that PAF-PAFR is
involved in the regulation of a set of protein tyrosine
kinase and onco-proteins including Src and FAK in ovar-
ian cancer cell proliferation and progression [15]. To
investigate whether PAF-PAFR may play significant roles
in malignant transformation in BRCA1-mutant HOSE
cells, we have investigated both Src and FAK expression
pattern in wild type HOSE-E6E7 and BRCA1-mutant
ovarian epithelial cells (HOSE-636 and HOSE-642).
There was no detectable Src protein expression in
BRCA1-mutant HOSE cells by western blot (data not
shown). We found that after 20 min of PAF treatment,
phosphor-FAK was not changed in wild type HOSE cells,
while there were significant increases of phosphorylation
of FAK (p-FAK) in both BRCA1-mutant HOSE-642 and
HOSE-636 cell lines (Fig. 6A). The total FAK protein
expression was also induced by PAF treatment in HOSE-
642 and HOSE-636 cells, but not in wild type HOSE-
E6E7 cells (Fig. 6AB). Using co-immune precipitation,
our data showed that both phosphor-FAK protein and
PAFR can be cross-detected by their specific antibodies
in western blots (Fig. 6C). Although we have not yet pro-
vided the detailed mechanisms of protein-protein inter-
action and the dynamic interactions of these protein
interactions, our preliminary data suggest that upon PAF
Figure 6 Activation of phosphor-FAK and STAT1 is associated with PAFR in BRCA1 mutant ovarian epithelial cells. (A) The specific phospho-
rylation of FAK in BRCA1-mutant at-risk HOSE-642 and HOSE-636 cells but not in wild type HOSE-E6E7 cells. (B) Summary of total FAK protein and phos-
phor-FAK protein induced by PAF treatment in wild type and BRCA1-mutant ovarian epithelial cells. The significant increases (*p < 0.05, **p < 0.01) 
were compared to the control cells treated with equal volume of DMSO (as 100%). (C) Protein-protein interaction between PAFR and FAK was detect-
ed by co-immune precipitation. Antibodies against PAFR and FAK were used for immune precipitation and incubated with protein lysate of HOSE-
642 cells with 10 nm PAF treatment, and non-specific IgG was used as negative control. The immune precipitated protein complex was separated on 
SDS gels and detected by FAK and PAFR antibodies, respectively. (D). Protein-protein interaction between FAK and STAT1 was detected either by im-
mune depletion assay or by co-immune precipitation with phosphor- and non-phospho antibodies of STAT1 and FAK. (E) Simplified scheme to show 
the integrative signal cascade and activation of PAFR, FAK, and STAT1 as early events of malignant transformation in BRCA1-mutant at-risk ovarian 
epithelium, particularly under the inflammatory conditions mediated lipid signaling (i.e. PAF).Zhang et al. Reproductive Biology and Endocrinology 2010, 8:74
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treatment and binding to PAFR, the PAF-mediated
inflammation signal could be transduced from extracellu-
lar domain of PAFR to FAK through protein-protein
interaction in BRCA1-mutant HOSE-642 cells. A similar
co-immune precipitation approach demonstrated that
there are significant cross-immune reactions and protein-
protein interactions between FAK and STAT1, either by
p-FAK antibody immune depletion or by co-immune pre-
cipitation (Fig. 6D). While this observation may require
further validation in other BRCA1-mutant epithelial
cells, our data together with the previous findings of
FAK-STAT1 interaction in cell migration, adhesion
through protein-protein interaction and auto-phospho-
rylation [33,34] strongly suggest that the inflammatory
mediator PAF plays a significant role in inducing malig-
nant transformation of the at-risk epithelium through
activation of multiple targets and networking cascade of
PAFR, FAK and STAT1 in coordination with BRCA1-dys-
function in ovarian epithelial cells (Fig. 6E).
Discussion
BRCA1 is a tumor-suppressor gene in which germ-line
mutations lead to a predisposition of breast and ovarian
cancer [35]. Normal BRCA1 regulates multiple nuclear
processes including DNA repair and recombination,
checkpoint control of the cell cycle [36]. There is growing
interest in the identification of the early events and
molecular signals involved in the predisposition to cancer
associated with BRCA mutations [11]. The present study
provides the first evidence to demonstrate that BRCA1-
mutation related cancer risk and malignant transition
m a y  b e  a s s o c i a t e d  w i t h  a c c u m u l a t i o n  o f  p o t e n t  p r o -
inflammatory lipid PAF and over expression PAFR in
non-malignant ovarian epithelial cells. Over-expression
of PAFR has been observed in malignant melanoma [37]
and ovarian cancer [15]. We have found that PAFR is also
over expressed in non-cancerous BRCA1-mutant epithe-
lial cells of the ovarian surface and distal fallopian tube,
compared to the wild type normal HOSE cells and fallo-
pian tube surface epithelial cells. This observation may
require additional confirmation with a larger set of non-
malignant  BRCA1-mutant cells and tissue specimens.
However, our study provides clear evidence that potent
pro-inflammatory mediators such as phospholipid PAF
and its receptor PAFR play significant roles in inducing
anti-apoptosis and malignant potential of the at-risk epi-
thelial cells in coordination with BRCA1 dysfunction (Fig.
5 and 6).
In addition, we found that cell proliferation was
increased ~20% in all BRCA1-mutant HOSE cell lines by
PAF treatment. This was less than the induced effect
observed in many ovarian cancer cell lines (>100%
increase) [15], but significantly decreased cell prolifera-
t i o n  i n  n o r m a l  w i l d  t y p e  H O S E  c e l l  l i n e s .  M o r e o v e r ,
PAFR inhibitors blocked the PAF-induced cell prolifera-
tion and p-STAT expression in all BRCA1-mutant cell
lines. This suggests that over expression of PAFR could be
an essential sensor for the BRCA1-mutant surface epithe-
lial cells to probe potent lipid inflammatory mediators
found in the micro-environment, including the condi-
tions of incessant ovulation cycles [38,39]. Correspond-
ingly, PAF-induced differential effects in cell
proliferation, cell cycle and apoptosis in the wild type and
non-malignant BRCA1-mutant HOSE cells provide addi-
tional confirmation that BRCA1-mutation and dysfunc-
tion is associated with the phenotypic PAF response,
especially under inflammatory conditions through the
PAFR pathway (Fig. 5). These combined findings suggest
that dysfunction of BRCA1 and over expression of PAFR
may contribute and account for the greater likelihood of
malignant transformation of BRCA1-mutant at-risk epi-
thelial cells, compared to wild type ovarian or tubal epi-
thelium.
Signal transducers and activators of transcription
(STATs) are a family of cytoplasmic proteins that func-
tion as signal messengers and transcription factors
involved in cellular responses to cytokines and growth
factors [40]. A line of evidence supports that STAT path-
ways play a significant role in malignant transformation
[8,41]. For example, a recent report showed that STAT1
phosphorylation determines Ras oncogenicity through
p27 protein [42]. Activated STAT1, STAT3 and STAT5
are often observed in solid and liquid tumors, and are
required for tumor transformation and progression
which involves a set of oncogenes such as EGFR, Ras, Src,
and FAK [8,43-45]. Here we found that phosphorylation
of STAT1, as well as STAT4 and STAT6 (not shown) were
simultaneously activated by PAF treatment in BRCA1-
mutant ovarian cancer cells (UWB1). Activated STAT1
phosphorylation was further confirmed in two additional
BRCA1-mutant HOSE cell lines, but not shown in wild
type HOSE-E6E7 and ovarian cancer (OVCA429) cells
(Fig. 4). In addition, PAF-induced STAT1 phophorylation
was partially blocked by PAFR inhibitors in BRCA1-
mutant HOSE-642 and UWB1 cells. This suggests that
PAFR is involved in STAT1 activation in BRCA1-mutant
HOSE cells. In the BRCA1-wild type cells, functional
BRCA1, as a tumor suppressor, acts in concert with
STAT1 to activate transcription of a subset of IFN-γ gene
targets and growth inhibition by cytokine [46]. Here we
provide independent evidence that coordination of
abnormal function of BRCA1 and activation STAT1
phosphorylation could induce HOSE cell proliferation
and anti-apoptosis in BRCA1-mutant cells, particularly
under inflammatory conditions.
Focal Adhesion Kinase (FAK) is a key mediator of sig-
naling induced by integrins that play an instrumental role
in many cellular functions including cell survival, prolif-Zhang et al. Reproductive Biology and Endocrinology 2010, 8:74
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eration [47] and stem cell signaling [48]. FAK is often
associated with cancer transformation [44], progression,
and metastasis [15] through the site specific phosphor-
activation. Our findings are consistent with many other
observations that FAK directly interacts with STAT1
[33,34], through phosphorylation of FAK to regulate the
cellular functions such as cell apoptosis, migration, inva-
sion and metastasis [49-51]. Although further investiga-
tion is required to confirm this finding in different
BRCA1-mutant cell lines, our data suggests that FAK may
have distinct activation pathways in non-malignant
BRCA1-mutant epithelial cells and in wild type malignant
progressive cells [51]. Nevertheless, the evidence for the
assignation of the roles of inflammatory lipids, including
PAF through paracrine regulation in cancer initiation,
particularly in BRCA-mutant epithelial cells is likely as
one of key mechanisms, but require further investigation.
It may be restricted to specific situations, depending on
mutation sites, tissue type and microenvironment. Here
we provided a unique BRCA1-mutant at-risk in vitro
model and demonstrated an evidence that coordinated
activation of PAF-PAFR, and FAK and STAT pathways,
with the abnormal BRCA1 functions may contribute to
the significant increases of malignant potential and early
events of tumor transformation in at-risk ovarian epithe-
lium (Fig 6E). This in vitro at-risk ovarian epithelium may
represent a valuable model to understand the early
molecular events of malignant transformation and devel-
opment. Certainly, it requires further molecular
approaches including networking pathway and target
knock-down in vitro and in vivo models to confirm that
the signal axis of PAF/PAFR-FAK-STAT pathway is signif-
icantly mediated in the early events of ovarian epithelial
malignant development.
Conclusions
Our findings showed that PAFR was over expressed in
BRCA1-mutant ovarian and fallopian tubal epithelial
cells, PAF specifically induced phosphorylation of FAK
and STAT1 in BRCA1-mutant ovarian epithelial cells,
and associated with protein-protein interaction between
PAFR and FAK and FAK and STAT1. These findings
strongly suggest that potent inflammatory lipid media-
tors such as P AF and its receptor (P AFR) are not only
involved in cancer progression and metastasis, but they
are also significantly involved in early malignant transfor-
mation through phosphor-FAK/STAT1 networking and
anti-apoptosis pathway in BRCA1-mutant dysfunctional
at-risk ovarian epithelium.
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